<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-88711</identifier>
<setSpec>1139-9287</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Pharmacogenetic studies on the antipsychotic treatment. Current status and perspectives</dc:title>
<dc:description xml:lang="en">Based on present knowledge, in this work we review the importance of the pharmacogenetic tests in the treatment with antipsychotic drugs. Many association shave been reported between different genetic markers and response to treatment as well as to the appearance of adverse reactions. However, up to now, no &#147;prime&#148; biomarker capable of unequivocally predicting the clinical benefits of a specific treatment or its toxicity has been identified. The use of individual pharmacogenetic markers has been demonstrated to have little clinical utility, and therefore the combination of information obtained from the analysis of different genes seems to be a more promising strategy. Inclusion of pharmacogenetic tests in clinical trials conducted prospectively and that include a large number of cases could, undoubtedly, significantly contribute to the development of individualized medicine protocols (AU)</dc:description>
<dc:creator>Baiget, M</dc:creator>
<dc:creator>Carracedo, A</dc:creator>
<dc:creator>Martín, A</dc:creator>
<dc:creator>Gesteira, A</dc:creator>
<dc:creator>Barros, F</dc:creator>
<dc:creator>Cortés, A</dc:creator>
<dc:creator>Pérez, V</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">En este trabajo se revisa, a la luz de los conocimientos actuales, la relevancia de los estudios farmacogenéticos en el tratamiento con fármacos antipsicóticos. Se han descrito un gran número de asociaciones entre distintos marcadores genéticos y la respuesta al tratamiento, así como a la aparición de efectos adversos. Sin embargo, no se ha identificado aún ningún biomarcador &#147;estrella&#148; capaz de predecir de forma inequívoca el beneficio clínico de un determinado tratamiento ni su toxicidad. La utilización de marcadores farmacogenéticos individuales se ha demostrado de poca utilidad clínica, por lo que la combinación de la información obtenida del estudio de diversos genes parece una estrategia más prometedora. La inclusión de estudios farmacogenéticos en ensayos clínicos realizados de forma prospectiva incluyendo un elevado número de pacientes podría, sin duda, contribuir de forma significativa al desarrollo de protocolos de medicina personalizada (AU)</dc:description>
<dc:source>Actas Esp Psiquiatr;38(5): 301-316, sept.-oct. 2010. graf, tab, ilus</dc:source>
<dc:identifier>ibc-88711</dc:identifier>
<dc:title xml:lang="es">Estudios Farmacogenéticos del tratamiento con Antipsicóticos: Estado actual y perspectivas</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d32618^s22068</dc:subject>
<dc:subject>^d10790^s22039</dc:subject>
<dc:subject>^d32618^s22020</dc:subject>
<dc:subject>^d14542^s22020</dc:subject>
<dc:subject>^d3595^s22033</dc:subject>
<dc:subject>^d24311^s22033</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d5957^s22019</dc:subject>
<dc:subject>^d5957^s22039</dc:subject>
<dc:subject>^d3595^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d10790^s22045</dc:subject>
<dc:subject>^d14542^s22044</dc:subject>
<dc:subject>^d24208^s22033</dc:subject>
<dc:subject>^d14542^s22068</dc:subject>
<dc:type>article</dc:type>
<dc:date>201010</dc:date>
</metadata>
</record>
</ibecs-document>
